Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04834375 · ClinicalTrials.gov registry record · Phase 3
Randomized Open Investigation Determining Steroid Dose
A Phase 3 study, sponsored by Northwell Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 142
- Enrollment target
NCT04834375: Completed Phase 3 study, sponsored by Northwell Health.
NCT04834375 is a Phase 3 study that has completed, run by Northwell Health. The registered enrollment target is 142 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04834375, a Phase 3 study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 142 participants
- Enrollment target
Study Summary
Dexamethasone has been approved for the treatment of severe COVID-19, but higher doses of steroids may be more effective. The purpose of this research study is to compare the current standard dose of dexamethasone 6 mg to a higher, weight-based dosing (0.2 mg/kg with maximum dose of 20 mg) to determine if it would be more effective against COVID-19 pneumonia.
Primary Outcome
All cause mortality at 28 days. Comment: Primary outcome was all cause mortality at 28 days but the patients were followed until end of admission for the final disposition (death or discharge) which accounts for the differences in the primary outcome of mortality at 28 days and the total number of deaths at discharge
Interventions
- DRUG Weight-based dexamethasone dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2021-03-19 |
| Est. Completion | 2022-03-29 |
| Phase | Phase 3 |
What the finished NCT04834375 record still lists
NCT04834375 is an interventional study that assigns participants to a tested intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 1 intervention - of which Weight-based dexamethasone dose is the first listed.
NCT04834375 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04834375 about?
NCT04834375 is a clinical study titled "Randomized Open Investigation Determining Steroid Dose". Dexamethasone has been approved for the treatment of severe COVID-19, but higher doses of steroids may be more effective. The purpose of this research study is to compare the current standard dose of dexamethasone 6 mg to a higher, weight-based dosing (0.2 mg/kg with maximum dose of 20 mg) to determ...
What is the current status of trial NCT04834375?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 142 participants. The study started on 2021-03-19. Estimated completion is 2022-03-29.
What interventions are being tested in trial NCT04834375?
The interventions under investigation include: Weight-based dexamethasone dose (DRUG).
Who is sponsoring clinical trial NCT04834375?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04834375's enrollment target sits among peer trials
142 1559th of 2000 higher than 438 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI